1259011-99-8

Basic information

• Product Name: (±) tert-butyl 2-(aminomethyl)-4,4-difluoropiperidine-1-carboxylate
• Synonyms: (±) tert-butyl 2-(aminomethyl)-4,4-difluoropiperidine-1-carboxylate
• CAS NO: 1259011-99-8
• Molecular Weight: 250.289
• Mol File: 1259011-99-8.mol

Chemical Properties

• CAS DataBase Reference: (±) tert-butyl 2-(aminomethyl)-4,4-difluoropiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (±) tert-butyl 2-(aminomethyl)-4,4-difluoropiperidine-1-carboxylate(1259011-99-8)
• EPA Substance Registry System: (±) tert-butyl 2-(aminomethyl)-4,4-difluoropiperidine-1-carboxylate(1259011-99-8)

Safety Data

• Hazardous Substances Data: 1259011-99-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(±) tert-butyl 2-(aminomethyl)-4,4-difluoropiperidine-1-carboxylate is used as a synthetic intermediate for the development of various pharmaceuticals. Its unique structure allows it to be a key component in the synthesis of drugs with specific therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical industry, (±) tert-butyl 2-(aminomethyl)-4,4-difluoropiperidine-1-carboxylate is utilized as a synthetic intermediate for the production of agrochemicals. Its properties contribute to the development of effective compounds for agricultural applications.
Used in Academic Research:
(±) tert-butyl 2-(aminomethyl)-4,4-difluoropiperidine-1-carboxylate is used in academic research as a compound with potential pharmacological properties. Its unique structure and functional groups make it a valuable subject for studying various biological activities and interactions.

Upstream product

• 1259011-96-5 (±)-methyl 1-benzyloxycarbonyl-4,4-difluoropiperidine-2-carboxylate 
• 125104-19-0 (±)-methyl 1-benzyloxycarbonyl-4-oxopiperidine-2-carboxylate 
• 847029-99-6 1-benzyl 2-methyl 4-hydroxypiperidine-1,2-dicarboxylate 
• 144913-66-6 4-hydroxy-2-piperidine carboxylic acid methyl ester 
• 1255666-28-4 1-tert-butyl 2-methyl 4,4-difluoropiperidine-1,2-dicarboxylate 
• 1259011-98-7 tert-butyl 2-cyano-4,4-difluoropiperidine-1-carboxylate 
• 1259011-97-6 tert-butyl 2-carbamoyl-4,4-difluoropiperidine-1-carboxylate 
• 1454291-05-4 (±) tert-butyl 4,4-difluoro-2-(hydroxymethyl)piperidine-1-carboxylate 
• 281652-10-6 4,4-difluoropiperidine-1-formic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1454291-07-6 (±) tert-butyl 2-((1 ,3-dioxoisoindolin-2-yl)methyl)-4,4-difluoropiperidine-1-carboxylate 

Downstream Products

• 1259012-00-4 tert-butyl 2-((2-(5-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-ylamino)methyl)-4,4-difluoropiperidine-1-carboxylate 
• 1454290-38-0 (2-(((4,6-dimethylpyrimidin-2-yI)amino)methyl)-4,4-difluoropiperidin-1-yl)(5-methyl-2-(2H-1 ,2,3-triazol-2-yl)phenyl)methanone 
• 1454291-01-0 (RS)(4,4-difluoro-2-(((5-(trifluoromethyl)pyridin-2-yl)amino)methyl)piperidin-1-yl)(3-phenylpyridin-2-yl)methanone 

Relevant articles and documents

Inhibitors of influenza viruses replication

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

PROBLEM TO BE SOLVED: To provide inhibitors of influenza virus replication. SOLUTION: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient comprise administering to the biological sample or patient an effective amount of a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, where the values of structural formula (IA) are as described herein. A compound is represented by structural formula (IA) or a pharmaceutically acceptable salt thereof, where the values of structural formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle. COPYRIGHT: (C)2015,JPO&INPIT

4,4-DIFLUORO-PIPERIDINE-COMPOUNDS

The invention, in a first aspect relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is a 6-membered aromatic ring, or a 5- or 6-membered heteroaromatic ring comprising 1 to 3 heteroatoms selected from S, O and N,

4,4-DIFLUORO-PIPERIDINE-COMPOUNDS

The invention, in a first aspect relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is a 6-membered aromatic ring, or a 5- or 6-membered heteroaromatic ring comprising 1 to 3 heteroatoms selected from S, O and N,

INHIBITORS OF INFLUENZA VIRUSES REPLICATION

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

INHIBITORS OF HEPATITIS C VIRUS

The present application includes novel inhibitors of HCV, compositions containing such compounds, therapeutic methods that include the administration of such compounds.